Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.66 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.56 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7310720 | 0.93 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Sulfuric Acid SCHEMBL143603 | 0.91 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17280857 | 0.89 | SLC7A5 (0.71) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17278094 | 0.89 | SLC7A5 (0.71) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17280858 | 0.89 | SLC7A5 (0.71) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17280831 | 0.88 | SLC7A5 (0.69) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL1045800 | 0.88 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL5405168 | 0.87 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL7056008 | 0.87 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL13042191 | 0.85 | SLC6A9 (0.54) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | claimed |
| US-20170007598-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2017-01-12 | — | — | US | disclosed |
| US-20150141452-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2015-05-21 | — | — | US | disclosed |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-1761478-B1 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | TEVA PHARM FINE CHEMICALS SRL (IT) | 2008-09-03 | — | — | EP | disclosed |
| US-7217696-B2 | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof | A & D BIOSCIENCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050130908-A1 | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof | HOLICK MICHAEL F (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1487460-A2 | GLYCURONAMIDES, GLYCOSIDES AND ORTHOESTER GLYCOSIDES OF FLUOXETINE, ANALOGS AND USES THEREOF | A & D Bioscience, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003073988-A2 | GLYCURONAMIDES, GLYCOSIDES AND ORTHOESTER GLYCOSIDES OF FLUOXETINE, ANALOGS AND USES THEREOF | A & D BIOSCIENCE, INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141452-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A4 978/4885SLC6A2 1596/4885SLC6A3 702/4885 |
| US-20170007598-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A4 978/4885SLC6A2 1596/4885SLC6A3 702/4885 |
| US-20050130908-A1 | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof | PYGB, GBA3, GAA | SLC6A4 121/4885SLC6A2 130/4885SLC6A3 180/4885 |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A4 978/4885SLC6A2 1596/4885SLC6A3 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.